Hua Medicine is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action. Hua has successfully brought this compound into Phase 1 clinical trials in China with the goal of initiating Phase 2 trials by 3Q2014.
The company has also internally developed two earlier-stage compounds focused on a clinically-validated CNS target spanning multiple indications, including potential treatments for specific neurodegenerative disorders. Hua retains world-wide rights to both its in-licensed and internally developed products.